KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 24.55M | 22.57M | 19.37M | 17.23M | 15.09M | 14.71M | 10.05M | 0 |
| Revenue Growth % | 62.7% | 53.4% | - | 71.4% | - | - | - | - |
| Cost of Goods Sold | 11.65M | 11.14M | 10.52M | 9.6M | 8.54M | 8.88M | 8.66M | 0 |
| COGS % of Revenue | 47.43% | 49.37% | 54.31% | 55.71% | 56.61% | 60.37% | 86.11% | - |
| Gross Profit | 12.91M | 11.42M | 8.85M | 7.63M | 6.55M | 5.83M | 1.4M | 0 |
| Gross Margin % | 52.57% | 50.63% | 45.69% | 44.29% | 43.39% | 39.63% | 13.89% | - |
| Gross Profit Growth % | 97.13% | 95.95% | - | 446.39% | - | - | - | - |
| Operating Expenses | 47.67M | 43.18M | 37.73M | 55.84M | 27.15M | 24.96M | 21.75M | 12.29M |
| OpEx % of Revenue | 194.16% | 191.35% | 194.77% | 324.06% | 179.91% | 169.71% | 216.29% | - |
| Selling, General & Admin | 42.7M | 38.3M | 33.73M | 50.46M | 23.8M | 21.45M | 17.93M | 7.43M |
| SG&A % of Revenue | 173.91% | 169.74% | 174.12% | 292.8% | 157.69% | 145.85% | 178.29% | - |
| Research & Development | 4.97M | 4.88M | 4M | 5.39M | 3.35M | 3.51M | 3.82M | 4.86M |
| R&D % of Revenue | 20.25% | 21.62% | 20.65% | 31.25% | 22.22% | 23.85% | 38% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -34.76M | -31.75M | -28.88M | -48.21M | -20.6M | -19.13M | -20.35M | -12.29M |
| Operating Margin % | -141.59% | -140.73% | -149.08% | -279.77% | -136.52% | -130.07% | -202.4% | - |
| Operating Income Growth % | -68.75% | -65.96% | - | -136.93% | - | - | - | - |
| EBITDA | -39.16M | -29.38M | -26.85M | -46.38M | -18.71M | -17.27M | -16.85M | -12.21M |
| EBITDA Margin % | -159.52% | -130.21% | -138.61% | -269.11% | -124.01% | -117.37% | -167.57% | - |
| EBITDA Growth % | -109.29% | -70.18% | - | -175.28% | - | - | - | - |
| D&A (Non-Cash Add-back) | -4.4M | 2.37M | 2.03M | 1.84M | 1.89M | 1.87M | 3.5M | 75K |
| EBIT | 0 | -30.85M | -23.88M | -49.25M | -19.96M | -19.21M | -20.38M | -12.23M |
| Net Interest Income | 0 | -105K | 255K | -104K | -1.16M | -1.4M | -1.94M | -847K |
| Interest Income | -10.09M | 1.8M | 2.17M | 1.66M | 628K | 0 | 0 | 0 |
| Interest Expense | 1.89M | 1.9M | 1.91M | 1.76M | 1.78M | 1.4M | 1.94M | 847K |
| Other Income/Expense | 633K | -996K | 3.08M | -2.8M | -1.14M | -1.48M | -1.96M | -787K |
| Pretax Income | -34.13M | -32.75M | -25.79M | -51.01M | -21.74M | -20.61M | -22.31M | -13.08M |
| Pretax Margin % | -139.02% | -145.14% | -133.15% | -296% | -144.08% | -140.13% | -221.91% | - |
| Income Tax | 35K | 34K | 33K | 102K | 18K | 8K | -27K | 57K |
| Effective Tax Rate % | -0.1% | -0.1% | -0.13% | -0.2% | -0.08% | -0.04% | 0.12% | -0.44% |
| Net Income | -34.17M | -32.78M | -25.83M | -52.05M | -21.51M | -20.37M | -22.28M | -13.13M |
| Net Margin % | -139.16% | -145.29% | -133.32% | -302.05% | -142.54% | -138.46% | -221.64% | - |
| Net Income Growth % | -58.85% | -60.96% | - | -133.59% | - | - | - | - |
| Net Income (Continuing) | 0 | -32.78M | -25.83M | -51.11M | -21.76M | -20.62M | -22.28M | -13.13M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 16.16M | 16.41M | 0 | 0 |
| EPS (Diluted) | -0.61 | -0.64 | -0.50 | -2.21 | -0.50 | -0.48 | -0.45 | -0.27 |
| EPS Growth % | -22% | -33.33% | - | -391.11% | - | - | - | - |
| EPS (Basic) | -0.61 | -0.64 | -0.50 | -2.21 | -0.50 | -0.48 | -0.45 | -0.27 |
| Diluted Shares Outstanding | 52.84M | 51.38M | 51.3M | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M |
| Basic Shares Outstanding | 52.84M | 51.38M | 51.3M | 49.53M | 49.53M | 49.53M | 49.53M | 49.53M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |